Healthcare providers can easily order Myriad’s genetic tests for the more than 250 million patients within Epic’s network

Myriad to establish new Walter Gilbert Research and Innovation Center Company also cited among 2022 Top Workplaces USA National List by Energage

BRACAnalysis CDx is now the only germline test approved by FDA as a companion diagnostic for treatment of HER2 negative high-risk early-stage breast cancer

Company launches Precise™ Tumor test, part of a comprehensive suite combining germline, tumor and companion diagnostics in one easy-to-access solution

Myriad Genetics announced financial results for its fourth quarter and year ended Dec. 31, 2021.

Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer

Myriad Genetics announced financial results for its third quarter ended September 30, 2021 and provided an update on recent business performance and strategic transformation plans.